Q.May Wang
Eli Lilly and Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Q.May Wang.
Journal of Virology | 2002
Q.May Wang; Michelle A. Hockman; Kirk A. Staschke; Robert B. Johnson; Katharine A. Case; Jirong Lu; Steve Parsons; Faming Zhang; Radhakrishnan Rathnachalam; Karla Kirkegaard; Joseph M. Colacino
ABSTRACT The NS5B RNA-dependent RNA polymerase encoded by hepatitis C virus (HCV) plays a key role in viral replication. Reported here is evidence that HCV NS5B polymerase acts as a functional oligomer. Oligomerization of HCV NS5B protein was demonstrated by gel filtration, chemical cross-linking, temperature sensitivity, and yeast cell two-hybrid analysis. Mutagenesis studies showed that the C-terminal hydrophobic region of the protein was not essential for its oligomerization. Importantly, HCV NS5B polymerase exhibited cooperative RNA synthesis activity with a dissociation constant, Kd , of ≈22 nM, suggesting a role for the polymerase-polymerase interaction in the regulation of HCV replicase activity. Further functional evidence includes the inhibition of the wild-type NS5B polymerase activity by a catalytically inactive form of NS5B. Finally, the X-ray crystal structure of HCV NS5B polymerase was solved at 2.9 Å. Two extensive interfaces have been identified from the packing of the NS5B molecules in the crystal lattice, suggesting a higher-order structure that is consistent with the biochemical data.
Journal of Virology | 2000
C. Cheng Kao; Xueyong Yang; Allen D. Kline; Q.May Wang; Donna Barket; Beverly A. Heinz
ABSTRACT The RNA-dependent RNA polymerase (RdRp) from hepatitis C virus (HCV), nonstructural protein 5B (NS5B), has recently been shown to direct de novo initiation using a number of complex RNA templates. In this study, we analyzed the features in simple RNA templates that are required to direct de novo initiation of RNA synthesis by HCV NS5B. NS5B was found to protect RNA fragments of 8 to 10 nucleotides (nt) from RNase digestion. However, NS5B could not direct RNA synthesis unless the template contained a stable secondary structure and a single-stranded sequence that contained at least one 3′ cytidylate. The structure of a 25-nt template, named SLD3, was determined by nuclear magnetic resonance spectroscopy to contain an 8-bp stem and a 6-nt single-stranded sequence. Systematic analysis of changes in SLD3 revealed which features in the stem, loop, and 3′ single-stranded sequence were required for efficient RNA synthesis. Also, chimeric molecules composed of DNA and RNA demonstrated that a DNA molecule containing a 3′-terminal ribocytidylate was able to direct RNA synthesis as efficiently as a sequence composed entirely of RNA. These results define the template sequence and structure sufficient to direct the de novo initiation of RNA synthesis by HCV RdRp.
Journal of Virology | 2003
Vincent J.-P. Lévêque; Robert B. Johnson; Stephen Parsons; Jianxin Ren; Congping Xie; Faming Zhang; Q.May Wang
ABSTRACT The NS5B RNA-dependent RNA polymerase encoded by the hepatitis C virus (HCV) is a key component of the viral replicase. Reported here is the three-dimensional structure of HCV NS5B polymerase, with the highlight on its C-terminal folding, determined by X-ray crystallography at 2.1-Å resolution. Structural analysis revealed that a stretch of C-terminal residues of HCV NS5B inserted into the putative RNA binding cleft, where they formed a hydrophobic pocket and interacted with several important structural elements. This region was found to be conserved and unique to the RNA polymerases encoded by HCV and related viruses. Through biochemical analyses, we confirmed that this region interfered with the binding of HCV NS5B to RNA. Deletion of this fragment from HCV NS5B enhanced the RNA synthesis rate up to ∼50-fold. These results provide not only direct experimental insights into the role of the C-terminal tail of HCV NS5B polymerase but also a working model for the RNA synthesis mechanism employed by HCV and related viruses.
Bioorganic & Medicinal Chemistry Letters | 2003
Shu-Hui Chen; Jason Lamar; Frantz Victor; Nancy June Snyder; Robert B. Johnson; Beverly A. Heinz; Mark Wakulchik; Q.May Wang
Abstract We describe herein the synthesis and biological evaluation of a series of tripeptidyl α-ketoamides as human rhinovirus (HRV) 3C protease inhibitors. The most potent inhibitor discussed in this manuscript, 4I, exhibited impressive enzyme inhibitory activity as well as antiviral activity against HRV-14.
Bioorganic & Medicinal Chemistry Letters | 2000
Ming Xian; Q.May Wang; Xinchao Chen; Kun Wang; Peng George Wang
Human rhinovirus (HRV) 3C protease was inactivated by a series of S-nitrosothiols. These compounds exhibited different inhibitory activities in a time- and concentration-dependent manner with second-order rate constants (kinact/K(I)) ranging from 131 to 5360 M(-1) min(-1). The inactive enzyme could be re-activated by DTT, GSH and ascorbate, which indicated the inactivation mechanism was through an S-transnitrosylation process.
Bioorganic & Medicinal Chemistry Letters | 1997
Louis Nickolaus Jungheim; Jeffrey Daniel Cohen; Robert B. Johnson; Elcira C. Villarreal; Mark Wakulchik; Richard J. Loncharich; Q.May Wang
Abstract Homophthalimides 2a and 3a were found to be inhibitors of Rhinovirus 3C protease through a blind screening effort. SAR studies resulted in compound 3g, which exhibited improved enzyme inhibition, in addition to whole cell antiviral activity. Molecular modeling studies suggest a preferred enzyme/inhibitor interaction, and LC/MS experiments confirmed tight/covalent binding of 3g to the enzyme.
Bioorganic & Medicinal Chemistry Letters | 1999
Shankar Venkatraman; Jian she Kong; Sanjay Nimkar; Q.May Wang; Jeffrey Aubé; Robert P. Hanzlik
A series of azapeptides was prepared and assessed as inhibitors of the human rhinovirus 3C protease. Boc-VLFaQ-OPh was a slow-turnover substrate that gave transient (ca. 1-2 h) inhibition as it underwent hydrolysis. Boc-VLFaG-OPh gave very slow but essentially irreversible inhibition.
Journal of Biological Chemistry | 1999
Gregory A. Cox; Robert B. Johnson; James A. Cook; Mark Wakulchik; Melvin G. Johnson; Elcira C. Villarreal; Q.May Wang
A purified recombinant human rhinovirus-14 3C protease preparation contained only ∼50% active enzyme as titrated using specifically designed irreversible 3C protease inhibitors. Analysis of the purified 3C protein by isoelectric focusing showed differently charged 3C isoforms that had isoelectric points (pI) of 8.3 (55%) and 9.0 (45%), with the latter one being consistent with the predicted pI of the human rhinovirus-14 3C protein. Further analysis indicated that the pI 8.3 protein was the deamidated form of 3C, and it displayed ∼10-fold reduced cleavage activity relative to the original 3C protease sample. Peptide mapping followed by sequence analysis revealed that a single asparagine, Asn-164, was deamidated to aspartic acid in the pI 8.3 isoform. Converting Asn-164 to Asp by site-directed mutagenesis resulted in a mutated 3C protease with extremely low activity, as seen with the pI 8.3 isoform, indicating a role of Asn-164 in substrate recognition and binding. In addition, the deamidated 3C protease was found to be present in vivo, and its abundance was related to the viral replication cycle. Moreover, mutant virus carrying Asp-164 showed reduced viability in infected cells. Taken together, our data suggest that 3C protein deamidation plays a role in the regulation of its enzymatic activity.
Biochemical and Biophysical Research Communications | 2000
Xin-Lai Sun; Robert B. Johnson; Michelle A. Hockman; Q.May Wang
Bioorganic & Medicinal Chemistry Letters | 2004
Yvonne Yip; Frantz Victor; Jason Lamar; Robert B. Johnson; Q.May Wang; Donna Barket; John Irvin Glass; Ling Jin; Lifei Liu; Daryl Venable; Mark Wakulchik; Congping Xie; Beverly A. Heinz; Elcira C. Villarreal; Joe Colacino; Nathan Yumibe; Mark Joseph Tebbe; John E. Munroe; Shu-Hui Chen